Table 1.
Characteristics of patients with R/R B-ALL.
| Characteristics | R/R B-ALL patients (N = 39) |
|---|---|
| Age (years) | 13 (1–57) |
| <18 | 27 (69.2) |
| 18–30 | 5 (12.8) |
| 31–60 | 7 (18.0) |
| Gender (male/female) | 22/17 |
| Number of previous chemotherapies | 4 (2–15) |
| 2–4 | 22 (56.4) |
| 5–10 | 15 (38.5) |
| >10 | 2 (5.1) |
| Refractory disease (n/%) | 36 (92.3) |
| Relapsed disease (n/%) | 17 (43.6) |
| Bone marrow blasts ≥5% | 9 (23.1) |
| Extramedullary disease | 22 (56.4) |
| CNSL | 12 (30.7) |
| Fusion gene (n/%) | |
| BCR/ABL1 | 12 (30.8) |
| Othersa | 8 (20.5) |
| Gene mutation | |
| SH2B3 | 15 (38.5) |
| PAX5 | 13 (33.3) |
| Othersb | 23 (69.0) |
| WBC (×109/L) | 35.76 (0.70–850.60) |
| Lymphodepletion regimens | |
| Flu + Cy | 12 (30.8) |
| Non-Flu + Cy | 27 (69.2) |
| CAR-T cells | |
| Anti-CD19 | 25 (64.1) |
| Anti-CD19 + CD22 | 14 (35.9) |
Data were presented as median (range) or count (percentage).
B-ALL B cell acute lymphoblastic leukemia, CR complete remission, CNSL central nervous system leukemia, WBC white blood cell, Flu fludarabine, Cy cyclophosphamide, CAR-T chimeric antigen receptor T cells.
aOthers: E2A/PBX1, EVI1, MLL/AF4, TEL/AML1.
bOthers: PAX5, TP53, IL7R, FLT3, IKZF1, NT5C2, NOTCH1, PTEN, TET2.